Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 40

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 2
Chunk 40
---
 and dental implants. Bacterial infection of any biomaterial implants is always a concern. SINTX silicon
nitride has been shown to be resistant to bacterial colonization and biofilm formation, making it antibacterial. SINTX silicon nitride
products can be polished to a smooth and wear-resistant surface for articulating applications, such as bearings for hip and knee replacements.

We
believe that silicon nitride has a superb combination of properties that make it suited for long-term human implantation. Other biomaterials
are based on bone grafts, metal alloys, and polymers- all of which have well-known practical limitations and disadvantages. In contrast,
silicon nitride has a legacy of success in the most demanding and extreme industrial environments. As a human implant material, silicon
nitride offers bone ingrowth, resistance to bacterial and viral infection, ease of diagnostic imaging, resistance to corrosion, and superior
strength and fracture resistance, all of which claims are validated in our large and growing inventory of peer-reviewed, published literature
reports. We believe that our versatile silicon nitride manufacturing expertise positions us favorably to introduce new and innovative
devices in the medical and non-medical fields.

Antipathogenic
Applications: Today, there is a global need to improve protection against pathogens in everyday life. SINTX believes that by
incorporating its unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters,
sutures, and wound care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of
infection and disease. The discovery in 2020 that SINTX silicon nitride inactivates SARS-CoV-2, the virus which causes the disease
COVID-19, has opened new markets and applications for our material. We presently manufacture advanced ceramic powders and components
in our manufacturing facilities based in Salt Lake City, Utah. The SINTX Salt Lake City facility is registered with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being
ISO 9001:2015, ISO 13485:2016 certified, and ASD9100D certified. The Company’s products are primarily sold in the United States.

19

Components of our Results of Operations

We manage our business within one reportable segment,
which is consistent with how our management reviews our business, makes investment and resource allocation decisions and assesses operating
performance.

Revenue

Our product revenue is